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p-Aminosalicylic acid (PAS) conjugated to maleylated bovine serum albumin (MBSA) was taken up
efficiently through high-affinity MBSA-binding sites on macrophages. Binding of the radiolabeled conjugate to
cultured mouse peritoneal macrophages at 4°C was competed for by MBSA but not by PAS. At 37°C, the
radiolabeled conjugate was rapidly degraded by the macrophages, leading to release of acid-soluble
degradation products in the medium. The drug conjugate was nearly 100 times as effective as free PAS in killing
the intracellular mycobacteria in mouse peritoneal macrophages infected in culture with Mycobacterium
tuberculosis. The killing of intracellular mycobacteria mediated by the drug conjugate was effectively prevented
by simultaneous addition of excess MBSA (100 ,ug/mI) or chloroquine (3 ,uM) to the medium, whereas these
agents did not affect the microbicidal action of free PAS. These results suggest that (i) uptake of the PAS-MBSA
conjugate was mediated by cell surface receptors on macrophages which recognize MBSA and (ii) lysosomal
hydrolysis of the internalized conjugate resulted in intracellular release of a pharmacologically active form of
the drug, which led to selective killing of the M. tuberculosis harbored by mouse macrophages infected in
culture. This receptor-mediated modality of delivering drugs to macrophages could contribute to greater
therapeutic efficacy and minimization of toxic side effects in the management of tuberculosis and other
intracellular mycobacterial infections.
Mycobacterium tuberculosis owes its pathogenicity to its
ability to survive and proliferate within mononuclear phago-
cytes (5). It is estimated that every year about 10 million
persons develop tuberculosis and at least 3 million die from
the disease (16). The most important factor in the treatment
of tuberculosis is prolonged chemotherapy, which is often
associated with serious unwanted side effects (7, 24). In the
chemotherapy of such intracellular pathogens, it is neces-
sary to achieve relatively high levels of the drug in blood to
attain therapeutically effective concentrations in infected
cells, which presumably leads to adverse effects on healthy
tissues. The present challenge in the therapy of intracellular
infections, therefore, is to develop systems capable of deliv-
ering the drugs to the intracellular sites of action at relatively
low levels in blood (reviewed in reference 6). Multilamellar
liposomes are being explored for intracellular delivery of
antimicrobial drugs (1, 4, 20) because of their preferential
uptake by reticuloendothelial cells with various degrees of
success. Recently, we have developed an alternative ap-
proach for selective intracellular delivery of drugs to mac-
rophages (3, 15) by using endocytosis of macromolecular
drug conjugates mediated presumably by scavenger recep-
tors (2, 10, 17) present only on macrophages (and, to a lesser
extent, on some endothelial cells). We have shown that
effective chemotherapy of experimental leishmaniasis in
hamsters can be achieved by homing an antileishmanial
drug, methotrexate, to macrophages by using maleylated
bovine serum albumin (MBSA) as the carrier to which the
drug was chemically conjugated (3, 15). In this study, we
investigated the possibility of using MBSA as a vehicle for
intracellular delivery of an antimycobacterial drug, p-ami-
nosalicylic acid (PAS), to cultured mouse peritoneal macro-
* Corresponding author.
t Communication IMT-003/90 from the Institute of Microbial
Technology.
phages infected with M. tuberculosis. We chose PAS as the
targeted drug to determine whether the receptor-mediated
modality of uptake of the drug reported here is likely to be
effective at lower dosages so that the toxic side reactions of
this potent antimycobacterial agent, and the drug of choice
until the 1970s, could be reduced to currently acceptable
levels (14).
MATERIALS AND METHODS
Organism. M. tuberculosis H37Ra obtained from N. K.
Ganguly, Postgraduate Institute of Medical Education and
Research, Chandigarh, India, was cultivated at 37°C for 7
days in Middlebrook 7H9 medium (Difco) containing Tween
80 and ADC enrichment. Bacteria were harvested in the
exponential growth phase. CFU were counted by serial
dilution on 7H10 agar plates (18). Cells were preserved in
1-ml aliquots at -70°C, thawed just before use, and sub-
jected to mild sonication to get single-cell suspensions.
Isolation of mouse peritoneal macrophages. Five-milliliter
volumes of heparinized phosphate-buffered saline (PBS)
were injected into the peritoneal cavities of BALB/c mice
weighing 30 to 40 g. The peritoneal fluids from 15 mice were
pooled, and the cells were collected by centrifugation (250 x
g, 10 min, room temperature). Cells were suspended in
medium A (RPMI 1640 medium [GIBCO] containing 10%
heat-inactivated fetal calf serum, 2 g of sodium bicarbonate
per liter, 2 mM glutamine, and 100 U of penicillin G per ml).
One-milliliter aliquots of the cell suspension (2 x 106 cells
per ml) were dispensed into six-well tissue culture clusters
(Costar, Cambridge, Mass.) containing 1 ml of medium A
and incubated at 37°C for 1 h in a humidified incubator
containing 5% CO2. Nonadherent cells were removed by
washing three times with sterile PBS. The monolayers were
incubated for 24 h in 2 ml of fresh medium A at 37°C. These
cells were used for further experiments.
Preparation of drug conjugate. Bovine serum albumin
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(Sigma Chemical Co., St. Louis, Mo.) was maleylated at pH
8.5 by using maleic anhydride (Sigma) as previously de-
scribed (11). The reaction mixture was dialyzed for 24 h
against 0.1 M ammonium bicarbonate solution and for 48 h
against glass-distilled water at 4°C, lyophilized, and stored at
-200C.
To prepare the drug conjugate, MBSA was allowed to
react with the sodium salt of PAS (Sigma) at pH 7.4 in the
presence of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
(Sigma) as previously described (8). Briefly, three reactants,
MBSA, PAS, and 1-ethyl-3-(3-dimethylaminopropyl)-carbo-
diimide were mixed at a molar ratio of 1:60:60, respectively,
in 3 ml of PBS and allowed to react for S h at room tem-
perature with constant shaking. The conjugate was sepa-
rated from other low-molecular-weight components by
Sephadex 0-50 gel filtration, dialyzed against PBS, and
stored frozen at -200C in small aliquots.
The amount of PAS bound to MBSA was determined by
fluorescence measurement in a KONTRON SFM-25 spec-
trofluorometer with 310 nm as the excitation wavelength and
405 nm as the emission wavelength. PAS showed a charac-
teristic fluorescence spectrum at this range (22), but MBSA
did not (data not shown). Protein concentration was deter-
mined by the biuret method. The molar ratio of PAS to
MBSA was 33:1.
Radioiodination of PAS-MBSA conijugate. The PAS-MBSA
conjugate was radioiodinated with Nal25I (Bhabha Atomic
Research Centre, Bombay, India) by the iodine monochlo-
ride method as previously described (9). The specific activity
of the labeled product was about 600 cpm/ng of protein.
Binding of [1251]PAS-MBSA to peritoneal macrophages at
4°C. Macrophage monolayers prepared in six-well tissue
culture clusters as described earlier were washed twice with
ice-cold PBS. Each well received 1 ml of medium B (RPMI
1640 medium without bicarbonate and fetal calf serum but
containing 1 mg of bovine serum albumin per ml) and the
concentrations of [1251]PAS-MBSA indicated (see Fig. 1).
The clusters were incubated at 4°C with gentle shaking.
After 2 h, the monolayers were washed three times with
ice-cold PBS containing bovine serum albumin (1 mg/ml) and
once with PBS. The cells were dissolved in 1 ml of 0.1 N
NaOH, and radioactivity was measured by placing an aliquot
in a gamma counter. Cellular protein content Was measured
by using alkaline copper reagent as previously described (9).
For competition experiments, each monolayer received 10
,ug of [125I]PAS-MBSA per ml with or without the concen-
trations of free PAS or free MBSA indicated (see Fig. 2) and
was processed as above.
Assay of uptake and degradation of [12'I]PAS.MBSA con-
jugate by peritoneal mnacrophages. Macrophage monolayers
prepared in six-well tissue culture clusters as described
earlier were washed twice with warm (37°C) PBS. Each well
received 1 ml of medium C (medium B with 2 g of sodium
bicarbonate per liter) containing the concentrations of
[125I]PAS-MBSA indicated (see Fig. 3 and 4), and the
clusters were incubated at 37°C in a humidified incubator
containing 5% CO2 for 5 h or various other periods. The
amounts of trichloroacetic acid-soluble degradation products
released in the medium were estimated as previously de-
scribed (9). The monolayers were washed, and cell-associ-
ated radioactivity and protein content were determined as
described above.
Infection of macrophage monolayers with M. tuberculosis.
Monolayers prepared as described above were washed twice
with PBS and incubated in a humidified incubator containing
5% CO2 with 2 ml of RPMI containing 1% fetal calf serum.
After 1 h, 1 ml of medium was withdrawn from each well and
replaced with 1 ml of a suspension of M. tuberculosis H37Ra
(107 cells per ml) grown as described earlier. After incuba-
tion at 37°C for 4 h, the monolayers were washed twice with
PBS to remove extracellular bacteria. Ziehl-Neelsen staining
of the monolayers showed the presence of 9 to 12 bacteria
per macrophage. Each monolayer then received 2 ml of
medium A and was incubated further at 37°C for 24 h.
Infected monolayers thus prepared were used to determine
the effects of drugs.
Drug action against intracellular growth of phagocytosed
mycobacteria. The concentrations of free PAS or PAS-
MBSA indicated (see Fig. 5) were added to each infected
monolayer prepared as described above, and incubation was
continued for 4 h at 37°C. Monolayers were washed three
times with PBS and incubated for 48 h in drug-free medium
A. The macrophages were then lysed by adding 2.5% (wt/
vol) sodium dodecyl sulfate (SDS), and appropriate dilutions
were plated on Middlebrook 7H10 agar as previously de-
scribed (18). CFU were counted after 3 weeks of incubation
at 37°C. SDS did not affect the viability or growth of
bacteria, as shown by control experiments (data not shown).
For determination of the time course of killing of M.
tuberculosis H37Ra by PAS-MBSA conjugate or free PAS,
infected monolayers (prepared as described earlier) were
incubated with 2 jig of PAS per ml in free or conjugated form
in medium A for various periods, washed, and incubated for
up to 48 h at 37°C in drug-free medium A. The cells were
lysed with SDS, and CFU were counted as described earlier.
RESULTS
Binding of [12SIJPAS-MBSA by peritoneal macrophages. To
determine the nature of the interaction of PAS-MBSA with
peritoneal macrophages, macrophage monolayers were in-
cubated at 4°C with increasing concentrations of the labeled
conjugate for 2 h, and after thorough washing, the radioac-
tivity associated with the cells was measured. The experi-
ments were done at 4°C to minimize the endocytic activities
of the macrophages so that the cell-associated radioactivity
largely reflects the binding of the ligand to discrete sites on
the cell surface. Binding of [1251]PAS-MBSA to the cells
followed saturation kinetics, indicating a limited number of
binding sites for the ligand (Fig. 1). Half-maximal binding
occurred at a concentration of about 1 ,ug of the labeled
conjugate per ml. Binding of radiolabeled PAS-MBSA was
inhibited by free MBSA (half-maximal inhibition occurred at
about 10 to 12 ,ug of MBSA per ml), but free PAS did not
affect binding of the drug conjugate (Fig. 2). Addition of
unlabeled PAS-MBSA to the medium eliminated binding of
[125I]PAS-MBSA to the macrophages as effectively as did
MBSA (data not shown).
Uptake and degradation of [125I]PAS-MBSA. When macro-
phages were incubated at 37°C with increasing concentra-
tions of [125I]PAS-MBSA, the cellular content of [125I]PAS-
MBSA, as well as trichloroacetic acid-soluble radioactivity
released in the medium, increased in a saturable fashion
(Fig. 3). Half-maximal saturation for uptake, as well as
degradation, of radiolabeled PAS-MBSA was achieved at a
conjugate concentration of about 6 jig of protein per ml.
The data in Fig. 4 show the time course of uptake and
degradation of [125I]PAS-MBSA by the macrophages. When
macrophages were incubated with [125I]PAS-MBSA at 37°C
for various times, cellular radioactivity reached a steady-
state plateau after about 2 h but acid-soluble radioactivity
continued to appear in the medium linearly, reflecting con-
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FIG. 1. Binding of [125I]PAS-MBSA to mouse peritoneal macro-
phages at 4°C. Each monolayer received 1 ml of ice-cold medium B
containing the indicated concentrations of [1251]PAS-MBSA. After 2
h at 4°C, the monolayers were washed and the amount of [125I]PAS-
MBSA bound to the cells was determined as described in Materials
and Methods. The results shown are means + standard deviations
for three independent experiments.
tinuing uptake and degradation of the conjugate. After about
4 h, the degradation process approached a steady state. At
this time, about six times as much [125I]PAS-MBSA was
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FIG. 3. Concentration dependence of uptake and degradation of
['25I]PAS-MBSA by mouse peritoneal macrophages at 370C. Each
monolayer received 1 ml of medium C containing the indicated
concentrations of [1251]PAS-MBSA. After incubation at 37°C for 5 h,
the amount of [1251]PAS-MBSA accumulated in the cells and the
125I-labeled trichloroacetic acid-soluble degradation products re-
leased in the medium were determined as described in Materials and
Methods. The results shown are means ± standard deviations for
three independent experiments.
was containea witnin tme cells. Killing of intracellular M. tuberculosis by free PAS and
PAS-MBSA conjugate. The data in Fig. 5 show the compar-
ative efficacies of free PAS and PAS-MBSA conjugate in
killing M. tuberculosis H37Ra harbored by cultured perito-
neal macrophages. During a 4-h exposure period, PAS (5
\,g/ml) in the conjugated form killed 80% of the intracellular(O ) PAS mycobacteria. In contrast, an equivalent amount of free PAS
(* )BMI3SA under the same conditions eliminated only 12.5% of the
mycobacteria. The superior antimycobacterial activity of
PAS-MBSA was more apparent at lower concentrations.
Thus, 50% of the intracellular bacteria were eliminated at a
concentration of 0.2 ,ug of PAS per ml presented as the
conjugate, whereas the free form killed only 0.5% of the
bacteria.
When infected macrophages were incubated for various
periods with PAS (2 ,ug/ml) in the conjugated form, about
55% of bacteria were eliminated within 3 h of exposure. In
contrast, exposure to the same concentration of the free drug
for the same duration killed only 10% of the bacilli (Fig. 6).
Exposure to PAS or PAS-MBSA did not affect the viability
of macrophages, as determined by the criterion of trypan
0 20 40 60 80 blue exclusion (data not shown).The antimycobacterial activity of the drug conjugate was
ConcentratiorL (g/ml) suppressed by an inhibitor of lysosomal functions, chloro-
quine, or an excess of MBSA, but neither chloroquine norEects of MB3SA and PAS on [1251]PAS-MBSA binding MBSA had any effect on the antibacterial activity of free
itoneal macrophages at 4°C. Each monolayer received PA (ab 1). ese datho that uptakety macro-
4d medium B containing 10 kg of [1211]PAS-MBSA per PAS (Table 1) These data show that uptake by macro-
dicated concentrations of eitherMBSA orPAS. After phages, followed by lysosomal degradation of the drug
r 2 h at 4°C, the monolayers were washed and the conjugate, was necessary to elicit the antimycobacterial
t51]PAS-MBSA bound to the cells was determined as activity of the drug conjugate. Addition of PAS-MBSA to an
daterials and Methods. The results shown are means ± axenic culture of M. tuberculosis did not affect the growth of
iations for three independent experiments. the mycobacteria (data not shown).
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FIG. 4. Time course of uptake and degradation of ['25I]PAS-
MBSA by macrophages at 37°C. Each monolayer received 1 ml of
medium containing 4 ,ug of [125I]PAS-MBSA per ml and was
incubated at 37°C. At the indicated times, the amount of 125I-labeled
trichloroacetic acid-soluble material in the medium and the amount
of [125I]PAS-MBSA in the cells were determined as described in
Materials and Methods. The results shown are means ± standard
deviations for three independent experiments.
DISCUSSION
Macrophages from different organs of a variety of animals
express high-affinity binding sites which recognize a number
of structurally disparate polyanionic macromolecules like
acetylated low-density lipoprotein, fucoidin, polyinosinic
acid, and MBSA. Binding is followed by internalization and
lysosomal degradation of the protein ligands (2, 10). The
determinants for recognition and uptake of such polyanionic
macromolecules, including MBSA, are present primarily on
macrophages (2, 3, 10, 17) and are referred to generically as
scavenger receptors which may comprise several distinct
molecular species (13, 19, 23).
This receptor system is beginning to find applications in
drug delivery research. Thus, previous work from our labo-
ratory has shown the utility of methotrexate coupled to
MBSA for elimination of intracellular amastigotes of Leish-
mania donovani and L. mexicana amazonensis in macro-
phages (3, 15). Similar results have been obtained by using
acetylated low-density lipoprotein as the vehicle for deliver-
ing antileishmanial agents (12). Also, acetylated low-density
lipoprotein-containing lipophilic muramyl tripeptide has
been shown to be delivered to macrophages, resulting in
enhancement of their tumoricidal activity (21). In this study,
we used MBSA as a homing device to deliver an antimyco-
bacterial agent, PAS, selectively to macrophages with the
expectation that uptake, followed by lysosomal degradation
of the PAS-MBSA conjugate, would lead to intracellular
release of a pharmacologically active form of the drug, as in
our previous studies with conjugates of methotrexate with
MBSA.
We conjugated PAS with MBSA by using a water-soluble
carbodiimide and determined whether the drug conjugate
binds to macrophages through the receptor which recognizes
MBSA. [125I]PAS-MBSA conjugate bound to macrophages
0 5 10 15 20
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FIG. 5. Comparison of the antimycobacterial actions of PAS and
PAS-MBSA in cultured mouse peritoneal macrophages. Macro-
phage monolayers were infected with M. tuberculosis as described
in Materials and Methods. Each infected monolayer containing 2 ml
of medium A received the indicated concentrations of PAS in the
free or conjugated form and were incubated at 37°C for 4 h. The
monolayers were then washed and incubated in 2 ml of drug-free
medium A. After 48 h, the macrophages were lysed and the number
of CFU of M. tuberculosis released in the lysate was determined as
described in Materials and Methods. The results shown are means +
standard deviations for five independent experiments.
in a saturable fashion at 4°C (Fig. 1), indicating the presence
of a limited number of binding sites on the cell surface.
Binding of ['25I]PAS-MBSA was inhibited by free MBSA but
not by free PAS (Fig. 2), indicating that the drug conjugate
was recognized by MBSA receptors. At 37°C, the radiola-
beled drug conjugate was efficiently taken up and degraded
by mouse peritoneal macrophages with saturation kinetics
(Fig. 3 and 4). Both MBSA and unlabeled PAS-MBSA
effectively competed for uptake and degradation of
[125I]PAS-MBSA (data not shown). Conjugation ofPAS with
MBSA significantly increased the antimycobacterial efficacy
of the drug. The conjugated drug at low concentrations was
nearly 100-fold as effective as the free drug (Fig. 5). Over a
5-h period, an average of about 17% of the bacteria were
eliminated per h by the PAS-MBSA conjugate (2 ,ug of PAS
per ml) but only 2.5% of the bacilli were killed per h by the
same concentration of free PAS (Fig. 6). Active lysosomal
functions are necessary to elicit the antibacterial activity of
the drug conjugate. The presence in the medium of 3 ,uM
chloroquine, an inhibitor of lysosomal functions, largely
abolished the microbicidal activity of the drug conjugate,
indicating that lysosomal hydrolysis of the drug conjugate is
necessary for intracellular release of the drug (Table 1). In
separate experiments, we found that chloroquine (3 ,uM)
effectively suppressed [125I]PAS-MBSA degradation (data
not shown). Chloroquine did not significantly affect the
antimycobacterial action of free PAS (Table 1). An excess of
MBSA in the medium effectively abolished the antimycobac-
terial action of PAS-MBSA but not that of free PAS. These
results, taken together, indicate that uptake of PAS-MBSA
through the MBSA receptors on macrophages, followed by
lysosomal degradation of the conjugate, led to intracellular
( 0 ) PAS
( ) PAS-MBSA
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FIG. 6. Time course of killing of M. tuberculosis in cultured
mouse peritoneal macrophages by PAS or PAS-MBSA. Each in-
fected monolayer containing 2 ml of medium A received 2 ,ug of PAS
per ml in the free or conjugated form. After incubation at 37°C for
the indicated interval, the monolayers were washed and the media
were replaced with 2 ml of drug-free medium A. After 48 h, the
macrophages were lysed and the number ofCFU of M. tuberculosis
released in the lysate was determined as described in Materials and
Methods. The number of CFU in the untreated control group of
infected macrophages did not change significantly over the 5-h
period of the drug pulse. The results shown are means ± standard
deviations of three independent experiments.
release of a pharmacologically active form of the drug, which
effectively eliminated the mycobacteria residing in the in-
fected macrophages.
Thus, we have shown that it is possible to increase the
antimycobacterial efficacy of PAS through conjugation of the
drug to MBSA. We have also shown that the polyanion
receptor system known to be present primarily on cells of
macrophage lineage (2, 10, 17) mediates delivery of the
conjugate to the macrophages. The efficiency of this receptor
system appears to be primarily responsible for an increase in
the effective concentration of the antitubercular agent within
macrophages. Inasmuch as macrophages are the primary cell
type in which various pathogenic mycobacteria reside and
proliferate, the receptor-mediated mode of drug delivery to
TABLE 1. Inhibition of antimycobacterial activity of PAS-MBSA
by MBSA and chloroquinea
No. of CFU/well (103)
Addition
(concn) Untreated PAS PAS-MBSA
control
None 921 507 276
MBSA (100 p.g/rml) 923 479 820
Chloroquine (3 ,uM) 875 415 847
a Macrophage monolayers infected with M. tuberculosis were incubated at
37'C with medium alone, MBSA, or chloroquine. After 2 h, PAS (5 ,g/ml)
was added in free or conjugated form and incubation was continued for 48 h.
Monolayers were then washed twice with PBS, and the macrophages were
lysed with SDS for determination of the number of CFU of M. tuberculosis
per well as described in Materials and Methods. The results shown are means
of three independent experiments.
macrophages described here merits serious consideration.
Further studies with different antimycobacterial drugs and
animal models, currently under way, will establish the value
of our approach for selective drug delivery in the chemother-
apy of tuberculosis and other diseases caused by mycobac-
teria.
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